Primary Record
Pemigatinib
- In stock
- 2,200 g
- Purity
- 98.4 %
- CAS
- 1513857-77-6
Compound Identifiers & Properties
- CAS
- 1513857-77-6
- PubChem CID
- 86705695
- SMILES
- CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5
- Canonical SMILES
- CCN1C(=O)N(c2c(F)c(OC)cc(OC)c2F)Cc2cnc3[nH]c(CN4CCOCC4)cc3c21
Names & Synonyms
- Pemigatinib
- Pemazyre
- pemigatinibum
- 1513857-77-6
- Pemigatinib?
- INCB054828
- Pemigatinib [INN]
- Pemigatinib [USAN]
- Pemazyre (TN)
- Fgfr inhibitor INCB054828
- Pemigatinib (Standard)
- Y6BX7BL23K
- RefChem:58318
- PEMIGATINIB [MI]
- PEMIGATINIB [JAN]
- Pemigatinib [USAN:INN]
- UNII-Y6BX7BL23K
- INCB54828
- INCB-054828
- PEMIGATINIB [WHO-DD]
- Pemigatinib (JAN/USAN/INN)
- DTXSID501027955
- GTPL9767
- INCB-54828
- Pemigatinib (INCB054828)
- CHEMBL4297522
- SCHEMBL15556271
- SCHEMBL29357782
- PEMIGATINIB [ORANGE BOOK]
- C24H27F2N5O4
- HCDMJFOHIXMBOV-UHFFFAOYSA-N
- MFCD31706227
- BDBM301310
- DTXCID401513523
- GLXC-21245
- HMS5086C06
- INCB 54828
- 1513857-77-6 (free base)
- EX-A4049
- EBC-27217
- NSC816556
- US10131667, Example 126
- AKOS040734158
- AT15587
- DB15102
- HY-109099R
- NSC-816556
- AC-36489
- AS-78489
- BP-44039
- DA-76699
- example 126 [WO2014007951]
- HY-109099
- CS-0039499
- S0088
- J3.745.391I
- D11417
- A936247
- EN300-22847362
- 3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholinomethyl)-1,3,4,6-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one
- B2693-006403
- 2H-Pyrrolo(3',2':5,6)pyrido(4,3-d)pyrimidin-2-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-8-(4-morpholinylmethyl)-
- 3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-8-(4-morpholinylmethyl)-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one
- 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-[(morpholin-4-yl)methyl]-1,3,4,7-tetrahydro-2Hpyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one
- Cyclopentanecarboxylic acid, 2-amino-, ethyl ester, (1R-cis)- (9CI)
- 11-(2,6-difluoro-3,5-dimethoxy-phenyl)-13-ethyl-4-(morpholinomethyl)-5,7,11,13-tetrazatricyclo[7.4.0.02,6]trideca-1,3,6,8-tetraen-12-one
- 11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-((morpholin-4-yl)methyl)-5,7,11,13-tetraazatricyclo(7.4.0.0^(2,6))trideca-1,3,6,8-tetraen-12-one
- 11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-(morpholin-4-ylmethyl)-5,7,11,13-tetraazatricyclo[7.4.0.0(2),?]trideca-1,3,6,8-tetraen-12-one
- 11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-(morpholin-4-ylmethyl)-5,7,11,13-tetrazatricyclo[7.4.0.02,6]trideca-1,3,6,8-tetraen-12-one
- 11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-[(morpholin-4-yl)methyl]-5,7,11,13-tetraazatricyclo[7.4.0.0,2,6]trideca-1(9),2(6),3,7-tetraen-12-one
- 11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-[(morpholin-4-yl)methyl]-5,7,11,13-tetraazatricyclo[7.4.0.02,6]trideca-1,3,6,8-tetraen-12-one
- 11-[2,6-bis(fluoranyl)-3,5-dimethoxy-phenyl]-13-ethyl-4-(morpholin-4-ylmethyl)-5,7,11,13-tetrazatricyclo[7.4.0.0^{2,6}]trideca-1(9),2(6),3,7-tetraen-12-one
- 197916-36-2
- 3-(2,6-DIFLUORO-3,5-DIMETHOXYPHENYL)-1-ETHYL-8-(MORPHOLIN-4-YLMETHYL)-1,3,4,7-TETRAHYDRO-2H-PYRROLO(3',2':5,6)PYRIDO(4,3-D)PYRIMIDIN-2-ONE
- 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3'',2'':5,6]pyrido[4,3-d]pyrimidin-2-one
- 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one
- 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo(4,5)pyrido(1,2-d)pyrimidin-2-one
- 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one
- 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholinomethyl)-3,4-dihydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2(7H)-one
- Pemigatinib; 2H-Pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-8-(4-morpholinylmethyl)-; 3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-8-(4-morpholinylmethyl)-2H-pyrrolo[3',2':5,6]pyrid